Mar 4 |
Entera Bio regains compliance with Nasdaq minimum bid price requirement
|
Mar 4 |
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
Feb 2 |
Entera Bio files to sell 16.5M ordinary shares for holders
|
Jan 12 |
Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying
|
Jan 3 |
Entera Bio receives extension from Nasdaq to regain compliance with minimum bid price rule
|
Jan 3 |
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
|
Dec 26 |
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
|
Nov 14 |
Entera Bio GAAP EPS of -$0.08
|
Nov 14 |
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
|
Nov 9 |
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
|